Clinigen Sustainability Profile
Clinigen Group plc, headquartered in the United Kingdom, is a leading global pharmaceutical and services company specialising in the provision of access to medicines. Founded in 2010, Clinigen has rapidly established itself in the healthcare industry, focusing on unlicensed and niche products, clinical trial services, and the management of complex supply chains. With a strong presence in Europe, North America, and Asia, Clinigen offers unique solutions that bridge the gap between pharmaceutical companies and patients. Their core services include the provision of clinical trial supplies and the management of access programmes, ensuring that patients receive critical treatments when they need them most. Clinigen's commitment to patient access and innovative solutions has positioned it as a trusted partner in the global healthcare landscape, achieving significant milestones in expanding its product offerings and market reach.
DitchCarbon Score
How does Clinigen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clinigen's score of 48 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Clinigen's reported carbon emissions
Clinigen, headquartered in Great Britain, has set ambitious climate commitments despite not having specific carbon emissions data available. The company has established a near-term target to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 42% by FY2030, using FY2023 as the base year. This target also extends to Scope 3 emissions, which include indirect emissions from air and road freight. Looking towards the long term, Clinigen aims for a significant reduction of 90% in absolute Scope 1, 2, and 3 GHG emissions by FY2040, again referencing FY2023 as the baseline. Additionally, Clinigen has committed to achieving net-zero GHG emissions across its entire value chain by FY2040. These targets align with the Science Based Targets initiative (SBTi) and are consistent with the reductions necessary to limit global warming to 1.5°C. Clinigen's climate strategy reflects a proactive approach to sustainability within the pharmaceuticals, biotechnology, and life sciences sector, demonstrating a commitment to reducing its environmental impact and contributing to global climate goals.
How Carbon Intensive is Clinigen's Industry?
How Carbon Intensive is Clinigen's Location?
Clinigen's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Clinigen has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
